PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1394146-4	1992	S49.1 and WEHI7.2 cells infected with bcl-2 but not control retrovirus also exhibited increased resistance to cell killing and DNA fragmentation induced by a wide variety of reagents, including the calcium ionophore ionomycin, the phorbol ester tetradecanoylphorbol acetate, the dihydrofolate reductase inhibitor methotrexate, the antimetabolite 1-beta-D-arabinofuranosylcytosine, and the microtubule inhibitor vincristine.	Tetradecanoylphorbol Acetate	245-273	B cell leukemia/lymphoma 2	Mus musculus	38-43	
15538571-12	2005	Moreover, PMA showed reinforcement, while doxorubicin showed significant antagonization, of the quercetin-mediated decrease in the expression of Bcl-2.	Tetradecanoylphorbol Acetate	10-13	B cell leukemia/lymphoma 2	Mus musculus	145-150	
11749964-3	2001	J774 cells overexpressing wild-type Bcl-2 resist oxidant-induced lysosomal leak as well as apoptosis, and this protection is amplified by pretreatment with phorbol 12-myristate 13-acetate (which promotes protein kinase C (PKC)-dependent phosphorylation of Bcl-2).	Tetradecanoylphorbol Acetate	156-187	B cell leukemia/lymphoma 2	Mus musculus	36-41	
11749964-3	2001	J774 cells overexpressing wild-type Bcl-2 resist oxidant-induced lysosomal leak as well as apoptosis, and this protection is amplified by pretreatment with phorbol 12-myristate 13-acetate (which promotes protein kinase C (PKC)-dependent phosphorylation of Bcl-2).	Tetradecanoylphorbol Acetate	156-187	B cell leukemia/lymphoma 2	Mus musculus	256-261	
8170972-5	1994	bcl-2-/- lymphocytes, however, could respond normally to various stimuli including anti-CD3, Con A, phorbol 12-myristate 13-acetate plus ionomycin, interleukin 2, lipopolysaccharide, and anti-IgM antibody.	Tetradecanoylphorbol Acetate	100-131	B cell leukemia/lymphoma 2	Mus musculus	0-5	
15063149-5	2004	To explore the mechanism of this effect, we employed flow cytometry to determine levels of p53, p21, bcl-2 and caspase proteins in the taxol-resistant cells, and found that the expression of the bcl-2 protein was markedly decreased and the expression of the caspase protein markedly increased after treatment with taxol in the presence of PMA.	Tetradecanoylphorbol Acetate	339-342	B cell leukemia/lymphoma 2	Mus musculus	195-200	
9484776-8	1998	Keratinocytes from the HK1.bcl-2 mice were significantly more resistant to cell death induction by U.V.-B, DMBA, and TPA, compared to control keratinocytes.	Tetradecanoylphorbol Acetate	117-120	B cell leukemia/lymphoma 2	Mus musculus	27-32	
9484776-9	1998	Furthermore, papillomas developed at a significantly greater frequency and shorter latency in the HK1.bcl-2 mice compared to control littermates following initiation with DMBA and promotion with TPA.	Tetradecanoylphorbol Acetate	195-198	B cell leukemia/lymphoma 2	Mus musculus	102-107	
9328437-9	1997	Fewer papillomas (P < 0.05) were observed at the low dose of TPA (1.25 microg) in mice carrying the bcl-2 knockout allele than in the wild-type mice, suggesting that reduction of the bcl-2 gene product affects the susceptibility of TG.AC mice to TPA-induced papillomas.	Tetradecanoylphorbol Acetate	64-67	B cell leukemia/lymphoma 2	Mus musculus	103-108	
9328437-9	1997	Fewer papillomas (P < 0.05) were observed at the low dose of TPA (1.25 microg) in mice carrying the bcl-2 knockout allele than in the wild-type mice, suggesting that reduction of the bcl-2 gene product affects the susceptibility of TG.AC mice to TPA-induced papillomas.	Tetradecanoylphorbol Acetate	64-67	B cell leukemia/lymphoma 2	Mus musculus	186-191	
9328437-11	1997	This suggests that at the higher dose of TPA, the effect of reduction in bcl-2 gene product was obscured.	Tetradecanoylphorbol Acetate	41-44	B cell leukemia/lymphoma 2	Mus musculus	73-78	
20734334-7	2011	Topical application of DMBA/TPA to the skin resulted in well-developed carcinomas associated with decreased expression of pro-apoptotic protein such as caspase 3 and enhanced expression of antiapoptotic protein such as bcl-2 when compared with the control counterparts.	Tetradecanoylphorbol Acetate	28-31	B cell leukemia/lymphoma 2	Mus musculus	219-224